Symbol="ELOX"
AssetType="Common Stock"
Name="Eloxx Pharmaceuticals Inc"
Description="Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is focused on developing ribonucleic acid modulator drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. The company is headquartered in Waltham, Massachusetts."
CIK="1035354"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="TRADE & SERVICES"
Industry="SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH"
Address="950 WINTER STREET, WALTHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="10116900"
EBITDA="-22733000"
PERatio="None"
PEGRatio="None"
BookValue="-7.46"
DividendPerShare="0"
DividendYield="0"
EPS="-14.24"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.732"
ReturnOnEquityTTM="-6.15"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-14.24"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="55"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="6.31"
EVToRevenue="-"
EVToEBITDA="0.141"
Beta="2.678"
num_52WeekHigh="19.2"
num_52WeekLow="1.696"
num_50DayMovingAverage="5.71"
num_200DayMovingAverage="4.981"
SharesOutstanding="2166400"
DividendDate="2017-12-20"
ExDividendDate="None"
symbol="ELOX"
open="4.59"
high="4.85"
low="4.55"
price="4.67"
volume="20782.00"
latest_trading_day="2023-08-18"
previous_close="4.61"
change="0.06"
change_percent="1.3015%"
aroon_positive_momentum_days="96"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="96"
Volume_recent_avg="892150"
Change_recent_avg="0.07"
Delta_recent_avg="0.96"
Variance_recent_avg="0.48"
Change_ratio_recent_avg="0.24"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="96"
Aroon_momentum_negative="4"
image_negative_thumbnail_id_1="1141"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0174.jpeg"
image_negative_thumbnail_id_2="1092"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0125.jpeg"
image_neutral_thumbnail_id_1="585"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0014.jpeg"
image_neutral_thumbnail_id_2="537"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0062.jpeg"
image_positive_thumbnail_id_1="661"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0047.jpeg"
image_positive_thumbnail_id_2="654"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0054.jpeg"
image_professor_thumbnail_id_1="1178"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
